Clinical Trial Update: NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for NEXT exploring subsequent exposure to tyrosine kinase inhibition at recurrence after adjuvant therapy in renal cell carcinoma; study te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: PrECOG, LLC. | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2017-04-20